Lipidor develops AKP02 as an alternative to existing psoriasis treatments through its spray formulation based on the proprietary AKVANO technology. The randomized, blinded phase III study is being conducted in collaboration with the contract research company Cliantha Research and the aim is to evaluate the efficacy and safety of AKP02 in comparison with an already approved reference drug for the treatment of mild to moderate psoriasis.
The first patient was recruited in September and now 15 clinics are running the study. More clinics combined with the winter season have caused the recruitment curve to develop exponentially, which means that it is now expected that the second half of the patient cohort will be recruited faster than the first.
The study is expected to include a total of 294 patients and the assessment is that recruitment will be completed in February. Lipidor then aims to present results from the study in April.
Tense anticipation for results
– The fact that half of the patients have now been recruited to the study is an incredibly important milestone. The start-up of the clinics is a critical phase and now all clinics are active, which creates good momentum. We are aiming for a fully recruited study according to the forecast communicated by the company's CRO, writes the company's CEO Ola Holmlund in a press release.
Lipidor's shares rose by about 12 percent on the news, and it is clear that the stock market is looking forward to the upcoming study results. In three months' time, the shares have traded up by almost 90 percent.